Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.44 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 3/20 | 0.42 |
| ▸ | NPY1R | P25929 | 2/20 | 0.42 |
| ▸ | NPY2R | P49146 | 2/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422984 | 0.94 | ACE (0.47) | NRP1OPRM1OPRK1NTSR2NTSR1 | |
| SCHEMBL29906667 | 0.92 | NRP1 (0.52) | NRP1OPRM1OPRK1NTSR2NTSR1 | |
| SCHEMBL30552516 | 0.92 | ACE (0.49) | NRP1OPRM1OPRK1NTSR2NTSR1 | |
| SCHEMBL29442101 | 0.92 | EPHA2 (0.45) | NRP1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL30173928 | 0.91 | EPHA2 (0.45) | OPRM1OPRK1NTSR2NTSR1NPY4R | |
| SCHEMBL29872595 | 0.90 | NRP1 (0.54) | NRP1OPRM1OPRK1NTSR2NTSR1 | |
| SCHEMBL30909415 | 0.90 | ACE (0.44) | NRP1OPRM1OPRK1ACE | |
| SCHEMBL30392004 | 0.89 | ACE (0.49) | NRP1NTSR2NTSR1ACEDPP4 | |
| SCHEMBL29906654 | 0.89 | NRP1 (0.50) | NRP1OPRM1OPRK1NTSR2NTSR1 | |
| SCHEMBL29721451 | 0.89 | ACE (0.45) | NRP1OPRM1OPRK1NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | NRP1 4766/4885OPRM1 2287/4885OPRK1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.